公司概覽
業務類別 --
業務概覽 HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
公司地址 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
電話號碼 +852 2121 8200
傳真號碼 +852 2121 8281
公司網頁 https://www.hutch-med.com
員工數量 1811
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Kin Hung Mark Lee Senior Vice President, Corporate Management and Communications -- 21/03/2025
Mr. Charles George Rupert Nixon Group General Counsel -- 21/03/2025
Mr. Hong Chen Executive Vice President and Chief Commercial Officer (China) -- 21/03/2025
Dr. Karen Jane Atkin Executive Vice President and Chief Operating Officer -- 21/03/2025
Dr. Zhenping Wu Executive Vice President, Pharmaceutical Sciences and Manufacturing -- 21/03/2025
Dr. Ming Michael Shi Executive Vice President, Head of R&D and Chief Medical Officer -- 21/03/2025
Mr. May Qingmei Wang Executive Vice President, Business Development & Strategic Alliances -- 21/03/2025
Mr. Johnny Cheng Chig FUNG Executive Director,Acting Chief Executive Officer and Chief Financial Officer 美元 443.02K 26/08/2025
 
董事會成員
董事會 職務 更新日期
Professor Tan Shao Weng Non-Executive Director 15/10/2025
Dr. Chaohong Hu Non-Executive Director 13/05/2025
Mr. Wong Tak Wai Non-Executive Director 13/05/2025
Professor Shu Kam Tony Mok Non-Executive Director,Senior Independent Director 13/05/2025
Ms. Ling Yang Non-Executive Director 21/03/2025
Mr. Johnny Cheng Chig FUNG Executive Director,Acting Chief Executive Officer and Chief Financial Officer 26/08/2025
Ms. Edith Shih Non-Executive Director,Company Secretary 21/03/2025
Mr. Dan Eldar Non-Executive Director,Chairman 21/03/2025
Dr. Renu Bhatia Non-Executive Director 13/05/2025
 
所屬ETF (更新日期: 07/03/2026 04:57)
代號 名稱 佔比% 持有日期
IXUSiShares Core MSCI Total Intl Stk ETF0.14%28/02/2026
VEUVanguard FTSE All-Wld ex-US ETF0.13%31/01/2026
SCHFSchwab International Equity ETF™0.12%28/02/2026
DFEMDimensional Emerging Markets Cr Eq 2 ETF0.08%27/02/2026
DFAEDimensional Emerging Core Equity Mkt ETF0.05%27/02/2026
VTVanguard Total World Stock ETF0.04%31/01/2026
ECNSiShares MSCI China Small-Cap ETF0.03%28/02/2026
CXSEWisdomTree China ex-State-Owd Entpr ETF0.03%27/02/2026
DFAXDimensional World ex US Core Eq 2 ETF0.03%27/02/2026
XSOEWisdomTree EmMkts ex-Stt-Ownd EntrprsETF0.02%27/02/2026
EEMSiShares MSCI Emerging Markets Sm-Cp ETF0.02%28/02/2026
VSGXVanguard ESG International Stock ETF0.01%31/01/2026
DFSEDimensional Emerging Mrkts Sstby Cr 1ETF0.01%27/02/2026
GINNGoldman Sachs Innovate Equity ETF0.01%27/02/2026
PDNInvesco RAFI Developed Mkts ex-US S-METF0.004%24/02/2026
MCHSMatthews China Discovery Active ETF0.002%27/02/2026
FDTSFirst Trust DevMkts exUS SC AlphaDEX®ETF0.0003%26/02/2026
FLAXFranklin FTSE Asia ex Japan ETF0.0003%28/02/2026
TLTDFlexShares Mstar DevMks exUS FctTilt ETF0.00003%27/02/2026
FLHKFranklin FTSE Hong Kong ETF<0.000001%24/06/2025
 1    2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.